AROMASIN stories
See what others are saying about AROMASIN.
Every time a case of breast cancer is diagnosed, a life changing journey begins. The stories behind these journeys are often emotional and inspiring. Below are the stories of two women who made the switch from tamoxifen to AROMASIN® (exemestane tablets). You'll also hear from experts who have experience with patients taking AROMASIN. Listening to what they have to say may help when it's time for you and your doctor to make decisions about your treatment.
To learn more about AROMASIN, please see the Full Prescribing and Patient Information.
AROMASIN® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with AROMASIN should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with AROMASIN should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and AROMASIN).
Copyright © 2009 Pfizer Inc. All rights reserved.
The product information provided in this site is intended only for residents of
the United States. The products discussed herein may have different product labeling
in different countries.
The health information herein is provided for educational purposes only and is not
intended to replace discussions with a health care provider. All decisions regarding
patient care must be made with a health care provider, considering the unique characteristics
of the patient.
AOU00471
